CD274 and non-small cell lung carcinoma: A recent meta-analysis evaluating outcomes from trials in patients with LAM NSCLC and ECOG PS ≤ 1, pretreated with an ICI, reported similar PFS rates to those we report here at 1 and 2 years of 13.2% and 7.7% in those with PD-L1 <1%, 21.9% and 7.4% for patients with PD-L1 expression 1–49%, and 27.5% and 21.3% for those with PD-L1 ≥50%.